Virtu Financial LLC Invests $674,000 in Altimmune, Inc. (NASDAQ:ALT)

Virtu Financial LLC purchased a new stake in Altimmune, Inc. (NASDAQ:ALT) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 109,759 shares of the company’s stock, valued at approximately $674,000. Virtu Financial LLC owned about 0.15% of Altimmune as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently added to or reduced their stakes in ALT. Larson Financial Group LLC acquired a new position in Altimmune in the 3rd quarter valued at about $31,000. Horizon Wealth Management LLC acquired a new position in Altimmune in the second quarter valued at approximately $66,000. PFG Investments LLC purchased a new position in Altimmune in the second quarter worth approximately $67,000. Principal Financial Group Inc. acquired a new stake in Altimmune during the second quarter worth $70,000. Finally, Verus Capital Partners LLC purchased a new stake in Altimmune in the second quarter valued at $82,000. Hedge funds and other institutional investors own 78.05% of the company’s stock.

Altimmune Price Performance

Shares of Altimmune stock opened at $9.03 on Friday. The stock has a market capitalization of $642.26 million, a price-to-earnings ratio of -5.83 and a beta of 0.15. The business has a 50-day moving average of $7.71 and a 200 day moving average of $7.06. Altimmune, Inc. has a 12 month low of $5.28 and a 12 month high of $14.84.

Altimmune (NASDAQ:ALT) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.03. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. The business had revenue of $0.01 million during the quarter. During the same period in the previous year, the business posted ($0.39) EPS. Equities research analysts anticipate that Altimmune, Inc. will post -1.36 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on ALT. HC Wainwright reiterated a “buy” rating and set a $12.00 price target on shares of Altimmune in a report on Thursday, November 14th. UBS Group assumed coverage on shares of Altimmune in a research report on Tuesday, November 12th. They set a “buy” rating and a $26.00 price target for the company. Two analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $20.00.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.